Clinical trial · Interventional

GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer

Phase II Trial of GM-CSF in Women With Asymptomatic Ovarian, Primary Peritoneal, or Tubal Carcinoma

NCT00157573CI-TRIAL-00027423completedPhase 2Results postedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

Granulocyte macrophage colony-stimulating factor (GM-CSF) is an immunostimulant and preliminary data suggests it may change the natural history of prostate cancer and melanoma. This study looks at ability of GM-CSF to alter disease progression in women who have recurrent but asymptomatic recurrence of their ovarian cancer.

Conditions

Conditions (2)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Fallopian Tube Cancer	Malignant Fallopian Tube Neoplasm	ALIAS	0.90
Ovarian Cancer	Malignant Ovarian Neoplasm	CURATED_EXACT	0.92

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
GM-CSF, sargramostim	Drug	—	UNRESOLVED

Design

Arms and outcomes

Arms (2)

type
EXPERIMENTAL
label
GM-CSF, Sargramostim Cohort 1
description
GM-CSF, Sargramostim 250 μg/m\^2 subcutaneous injection daily on days 1 to 14 in a 28-day cycle until disease progression or unacceptable toxicity for a median of 3 cycles.
interventionNames
1. Drug: GM-CSF, sargramostim
type
EXPERIMENTAL
label
GM-CSF, Sargramostim Cohort 2
description
GM-CSF, sargramostim 150 μg/m\^2 subcutaneous injection daily for 28 days in a 28-day cycle until disease progression or unacceptable toxicity fora median of 3 cycles. GM-CSF, sargramostim dose escalation was permitted up to 250 μg/m\^2 per day if applicable based on toxicity and white blood cell count.
interventionNames
1. Drug: GM-CSF, sargramostim

Primary outcomes (1)

measure

Eligibility

Eligibility (as posted)

Sex: Female
Minimum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

* Patients must have a history of histologic or cytologic diagnosis of primary ovarian, primary peritoneal or tubal carcinoma.
* Patients must be asymptomatic from their cancer.
* Patients must have evidence of recurrent carcinoma, as determined by:

* A rising cancer antigen 125 (CA-125) serum level greater than 35 U/mL or two successive rising values with the most recent value at least 3 times the nadir value.
* Or evidence of evaluable or measurable disease by x-ray or computed tomography (CT) scan.
* Patients may not receive concurrent antineoplastic therapy. All hormonal therapy used as a treatment modality (i.e. tamoxifen, arimidex, etc) must be stopped prior to treatment on protocol.
* Age \> 18 years.
* Eastern Cooperative Oncology Group (ECOG) performance status \< 2.

Exclusion Criteria:

* Known severe hypersensitivity to GM-CSF.
* Other coexisting malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ or concurrent superficial or stage IB endometrial carcinoma.
* Concomitant use of anti-neoplastic therapy.
* Treatment with a non-FDA approved or investigational drug within 30 days before Day 1 of trial treatment.
* Any unresolved chronic toxicity greater then Common Toxicity Criteria (CTC) grade 2 from previous anticancer therapy (except alopecia).
* Serum creatinine level greater than CTC grade 2 \[1.5 x upper limit normal (ULN)\].
* Pregnancy or breast feeding (women of childbearing potential).
* Severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) as judged by the investigator.
* Significant clinical disorder or laboratory finding that makes it potentially unsafe for the subject to participate in the trial as judged by the investigator.
* Patients currently receiving other investigational antineoplastic agents, on systemic chemotherapy or under radiation therapy treatment.
* Patients with clinical and/or radiographic evidence of current or impending bowel obstruction.
* Performance status \< 1.
* Ability to understand and the willingness to sign a written informed consent document.

References

Publications (1)

RESULTRoche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, Silver M, Tran CD, Seiden MV, Penson RT. Phase II trial of GM-CSF in women with asymptomatic recurrent mullerian tumors. Gynecol Oncol. 2010 Feb;116(2):168-72. doi: 10.1016/j.ygyno.2009.10.075. Epub 2009 Nov 18. PMID 19922985